Assay method for the carboxylic acid metabolite of clopidogrel in human plasma by gas chromatography mass spectrometry

被引:59
作者
Lagorce, P
Perez, Y
Ortiz, J
Necciari, J
Bressolle, F [1 ]
机构
[1] Fac Pharm Montpellier, Fac Pharm, Lab Pharmacocinet, F-34060 Montpellier 2, France
[2] Sanofi Rech, F-34082 Montpellier, France
[3] Sanofi Winthrop, Riells, Spain
来源
JOURNAL OF CHROMATOGRAPHY B | 1998年 / 720卷 / 1-2期
关键词
clopidogrel; SR26334;
D O I
10.1016/S0378-4347(98)00452-6
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
This paper describes a GC-MS method for the analysis of the carboxylic acid metabolite (SR26334, II) of methyl (+)-(S)-alpha-(o-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4H) -acetate hydrogensulfate (clopidogrel, SR 25990, I) in plasma and serum. The analytical procedure involves a robotic liquid-liquid extraction with diethyl ether followed by a solid-liquid extraction on C-18 cartridges. The derivatization process was performed using n-ethyl diisopropylethylamine and alpha-bromo-2,3,4,5,6-pentafluoro toluene. A structural analogue (III) of II, was used as internal standard. The 1/X-2 weighted calibration curve obtained in the range 5-250 ng/ml was well described by a quadratic equation. The extraction efficiency was better than 48% over the range studied; for the internal standard it averaged 51% at 50 ng/ml. Precision ranged from 3.6 to 15.8%, and accuracy was between 92 and 114%. Dilution has no influence on the performance of the method which could then be used to quantitate plasma samples containing up to 25000 ng/ml. The limit of quantification was 5 ng/ml. The method validation results indicate that the performance characteristics of the method fulfilled the requirements for assay methods for use in pharmacokinetic studies. (C) 1998 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:107 / 117
页数:11
相关论文
共 11 条
[1]   Validation of liquid chromatographic and gas chromatographic methods - Applications to pharmacokinetics [J].
Bressolle, F ;
BrometPetit, M ;
Audran, M .
JOURNAL OF CHROMATOGRAPHY B-BIOMEDICAL APPLICATIONS, 1996, 686 (01) :3-10
[2]   Clopidogrel [J].
Coukell, AJ ;
Markham, A .
DRUGS, 1997, 54 (05) :745-750
[3]  
GARDELL SJ, 1993, PERSPECTIVES DRUG DE, V3, P521
[4]  
Guillin M.-C., 1996, European Heart Journal, V17, P161
[5]   CLOPIDOGREL, A NOVEL ANTIPLATELET AND ANTITHROMBOTIC AGENT [J].
HERBERT, JM ;
FREHEL, D ;
VALLEE, E ;
KIEFFER, G ;
GOUY, D ;
BERGER, Y ;
NECCIARI, J ;
DEFREYN, G ;
MAFFRAND, JP .
CARDIOVASCULAR DRUG REVIEWS, 1993, 11 (02) :180-198
[6]  
KIEFFER G, 1989, THROMB HAEMOSTASIS, V62, P411
[7]   CLOPIDOGREL INHIBITS THE BINDING OF ADP ANALOGS TO THE RECEPTOR MEDIATING INHIBITION OF PLATELET ADENYLATE-CYCLASE [J].
MILLS, DCB ;
PURI, R ;
HU, CJ ;
MINNITI, C ;
GRANA, G ;
FREEDMAN, MD ;
COLMAN, RF ;
COLMAN, RW .
ARTERIOSCLEROSIS AND THROMBOSIS, 1992, 12 (04) :430-436
[8]   Reduction in extraction efficiency of charged particles from the ion source as the cause of matrix effects in the GC-MS analysis of drugs [J].
Ostheimer, D ;
Cremese, M ;
Wu, AHB ;
Hill, DW .
JOURNAL OF ANALYTICAL TOXICOLOGY, 1997, 21 (01) :17-22
[9]  
SALVI P, 1996, CLIN APPL THROMB HAE, V2, P35
[10]   ANALYTICAL METHODS VALIDATION - BIOAVAILABILITY, BIOEQUIVALENCE, AND PHARMACOKINETIC STUDIES [J].
SHAH, VP ;
MIDHA, KK ;
DIGHE, S ;
MCGILVERAY, IJ ;
SKELLY, JP ;
YACOBI, A ;
LAYLOFF, T ;
VISWANATHAN, CT ;
COOK, CE ;
MCDOWALL, RD ;
PITTMAN, KA ;
SPECTOR, S .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1992, 81 (03) :309-312